However, while initially exciting, several patients experienced worsening parkinsonism with sarizotan or with increasing doses, due to the fact that sarizotan not only antagonizes 5-HT1A receptors but also blocks the D4 DA receptor (Olanow et al., 2004). This evidence concerns the gene HTR1A and Parkinson disease.